Association of the TP53 codon 72 polymorphism and breast cancer risk: a meta-analysis

Meire Luzia Gonçalves¹, Sarah Moreira Borja¹, Jacqueline Andréia Bernardes Leão Cordeiro², Vera Aparecida Saddi¹,³,⁵, Flávio Monteiro Ayres⁴, Cesar Augusto Sam Tiago Vilanova-Costa⁵ and Antonio Márcio Teodoro Cordeiro Silva¹,⁵*

Abstract

This study was conducted in order to investigate the implications of the R72P polymorphism in the TP53 gene in breast cancer risk. The enlightenment of this matter might provide a piece of information about the potential implications of this polymorphism in patient risk. A meta-analysis was conducted considering a large sample size from studies with conflicting results on the R72P polymorphism in breast cancer patients. Relevant studies were selected from PubMed and SciELO databases for data extraction and statistical analysis. Database was built according to the continent and considering the genotype frequencies, sample size and genotyping methodology. The dominant models (RR vs RP + PP and RR + RP vs. PP), homozygous (RR vs. PP), heterozygous (RR vs. RP and RP vs. PP) and the allele (R vs. P) were used. Genotype frequencies were summarized and evaluated by χ² test of heterogeneity in 2×2 contingency tables with 95% CIs. Odds Ratios (OR) were calculated with a fixed-effect model (Mantel-Haenszel) or a random-effect model (DerSimonian-Laird) if the studies were considered homogeneous (P > 0.05) or heterogeneous (P < 0.05), respectively, using BioEstat® 5.0 software.

Supported by a large sample size composed by 25,629 cases and 26,633 controls from 41 studies, we found significant association between the R72P polymorphism in the TP53 gene and the breast cancer risk. The overall data shows an increased risk due to the P allele dominant model, but not in Asia where the risk was associated with the R allele and R dominant model.

Keywords: Arg72Pro; Genetic susceptibility; p53; R72P; Single nucleotide polymorphism; Breast cancer

Introduction

The R72P polymorphism in the TP53 gene results of the transversion G→C in the second position of the codon 72 at exon 4. Both the polymorphic alleles vary among ethnic groups (Dokianakis et al. 2000) and geographic location, where the P allele is more frequent toward the equator line purportedly as a protective factor against UV rays (Damin et al. 2006; Olivier et al. 2002). P53 variant proteins have an arginine (R) or a proline (P) encoded by codon 72, which differ in structure and function, specially concerning cell cycle progress (Chang-Claude et al. 2009; Schmidt et al. 2009; Thomas et al. 1999; Petitjean et al. 2007; Dumont et al. 2003).

Breast cancer is an heterogeneous sporadic or hereditary disease (Lima et al. 2006). The hereditary syndrome affects 10% of patients, of which 5% has high penetrance mutations in genes like BRAC1 and BRCA2 (BRCA1/2) (Pinto et al. 2007). BRCA1/2 and TP53 are susceptibility genes that confer high-risk of breast cancer (Oluwagbemiga et al. 2012). Evidences that the R72P polymorphisms in the TP53 gene can differently promote the transcription of BRAC1/2 have widely supported studies on R72P role in breast tumorigenesis (Sinilnikova et al. 2009; Lum et al. 2008; Osorio et al. 2008; Gochhait et al. 2007; Cavallone et al. 2008; Baynes et al. 2007; Tommiska et al. 2005; Martin et al. 2003; Huang et al. 2003), e.g., (1) the P variant binds greater to transcriptional machinery (Thomas et al. 1999) and thus shows higher rates of G1 arrest than the R variant protein (Petitjean et al. 2007; Gochhait et al. 2007); (2) the decreased efficiency of the P variant at triggering apoptosis (Chang-Claude et al. 2009; Dumont et al. 2003), mainly due to its decreased ubiquination by MDM2 (Sinilnikova et al. 2009).

* Correspondence: marciocmed@gmail.com
¹ Departamento de Medicina, Pontifícia Universidade Católica de Goiás, Av. Universitária 1.069, Setor Universitário, Goiânia, Goiás CEP 74.605-010, Brazil
² Programa de Pós-Graduação Stricto Sensu em Ciências Ambientais e Saúde, Pontifícia Universidade Católica de Goiás, Goiânia, Goiás CEP 74065-140, Brazil

Full list of author information is available at the end of the article

© 2014 Gonçalves et al; licensee Springer. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
2009; Lum et al. 2008; Gochhait et al. 2007; Francisco et al. 2010) and to its increased efficiency to bind the inhibitor of apoptosis-stimulating protein of p53 (iASPP) (Schmidt et al. 2009; Bergamaschi et al. 2006).

In the present study, a meta-analysis was conducted considering a large sample size from studies with conflicting results on the R72P polymorphism in breast cancer patients. The enlightenment of this matter might provide a piece of information about the potential implications of this polymorphism in patient’s risk.

Material and methods
Identification and eligibility of relevant studies
A literature search was conducted in SciELO (Scientific Electronic Library Online) and PubMed databases by using the keywords: p53, polymorphism, breast cancer. Additional studies were searched among the references surveyed in the databases. Eligible studies were selected regardless of sample size, but had to meet the following criteria of inclusion: (a) the studies were published from 2002 to 2012; (b) the association between the R72P polymorphism and breast cancer were investigated; (c) the studies were case-control design; (d) genotyping was carried out by molecular biology methods, such as PCR, RFLP-PCR and DNA sequencing; (e) the reference was published in English; (f) histological confirmation of breast cancer diagnosis was performed; and (g) the genotype distributions were available for estimating odds ratios (OR) and 95% confidence intervals (CI).

Data extraction
Two investigators independently extracted data and reached a consensus on all of the items. A third investigator took part of data extraction in case of disagreement in any of the items. The data extracted regarded country of origin, first author, and year of publication, number of cases and controls, and genotype frequencies.

Statistical analysis
In the current meta-analysis, the dominant models (RR vs RP + PP and RR + RP vs. PP), homozygous (RR vs. PP), heterozygous (RR vs. RP and RP vs. PP) and the allele (R vs. P) were used. Genotype frequencies were summarized and evaluated by \( \chi^2 \) test of heterogeneity in 2×2 contingency tables with 95% CIs (Böhning et al. 2002). Odds Ratios (OR) were calculated with a fixed-effect model (Mantel-Haenszel) or a random-effect model (DerSimonian-Laird) if the studies were considered homogeneous (\( P > 0.05 \)) or heterogeneous (\( P < 0.05 \)), respectively. The OR and their corresponding 95% CI were used to test the association between the 72 codon polymorphism and breast cancer. All analyses were performed with BioEstat® 5.0 software. To estimate a combined effect, OR were calculated for both fixed and random effect
analyses, by applying 95% CIs and individual or combined weights for the studies (Li et al. 2012; Conn et al. 2012; Manning et al. 2011; Higgins et al. 2008).

**Results and discussion**

**Study inclusion and characteristics**

A total of 492 studies were screened, of which three were found in both PubMed and SciELO. From the 489 studies screened, 218 were published before 2002 and 20 were reviews or published in another language than English, or both. The remaining 271 records were assessed for eligibility and 41 fulfilled the criteria of inclusion (Figure 1). From the selected studies, a database was built considering the continent, genotype frequencies, sample size and genotype methodology. All together, the 41 studies that met the inclusion criteria and were identified as eligible article, yielding 25,629 cases and 26,633 controls.

In the last 10 years, eligible studies on R72P polymorphism in the TP53 gene in breast cancer were mostly from Europe with 19 articles, followed by Asia, America and Africa with 14, 6 and 2, respectively. Subject’s age was collected, when available, showing that mean age of patients was 51.9 y.o. and of control subjects 48.1 y.o. The genotyping for p53 codon 72 polymorphism was performed using Polymerase Chain Reaction (PCR), Allele-Specific PCR (AS-PCR), Amplifluor®, GoldenGate® Genotyping Assay (GGA), PCR-Denaturing Gradient Gel Electrophoresis (PCR-DGGE), PCR-Restriction Fragment Length Polymorphism (PCR-RFLP), sequencing and Taqman PCR. Breast cancer patients and controls subjects were mainly heterozygous in Asia (50.1%; 48.0%) and Africa (43.9%; 49.7%), while the RR homozygous was predominant in America (53.6%; 54.5%) and Europe (54.1%; 53.4%). The R allele was predominant in breast cancer patients from America and Europe (73.3%, each), Africa (63.2%) and Asia (58.3%).

**Quantitative synthesis**

The dominant models RR + RP vs. PP and RR vs. RP + PP had OR calculated using a random-effect model. No association between breast cancer risk and the dominant model RR + RP vs. PP (OR = 1.09; 95% CI 0.98-1.22) was found (Figure 2 and Table 1). By the other hand, our findings for RR vs. RP + PP (OR = 1.11; 95% CI 1.02-1.21) showed a markedly increased risk of breast cancer associated with the RP and PP genotypes, considering the P
| Studies/continent | No. of case/control | RR + RP vs. PP OR (95% CI) | RR vs. RP + PP OR (95% CI) | R vs. P OR (95% CI) |
|-------------------|---------------------|---------------------------|---------------------------|---------------------|
| **Africa**        | Σ=189/181           | 1.13 (0.64-2.01)          | 1.40 (0.91-2.15)          | 1.16 (0.86-1.56)    |
| Trifa et al., 2010| 159/132             | 1.19 (0.65-2.19)          | 1.21 (0.75-1.96)          | 1.15 (0.83-1.61)    |
| Mabrouk et al., 2003| 30/49              | 0.78 (0.18-3.40)          | 2.32 (0.93-5.78)          | 1.59 (0.78-3.27)    |
| **America**       | Σ=6,483/8,011       | 0.99 (0.87-1.12)          | 1.05 (0.88-1.26)          | 0.98 (0.92-1.02)    |
| Damin et al., 2006| 118/202             | 2.05 (0.83-5.09)          | 2.22 (1.40-3.53)          | 1.79 (1.25-2.55)    |
| Aoki et al., 2009 | 72/90               | 1.78 (0.48-6.60)          | 2.47 (1.31-4.66)          | 1.85 (1.14-3.00)    |
| **Asia**          | Σ=2,570/2,833       | 1.21 (0.89-1.64)          | 1.08 (0.89-1.32)          | *1.09 (1.01-1.17)   |
| Lum et al., 2008  | 393/80              | 0.69 (0.37-1.30)          | 0.64 (0.39-1.06)          | 0.73 (0.51-1.03)    |
| Gochhait et al., 2007| 243/333            | 1.66 (1.12-2.46)          | 1.85 (1.28-2.67)          | 1.56 (1.23-1.92)    |
| **Europe**        | Σ=16,387/15,608     | 1.03 (0.95-11.25)         | 1.13 (1.00-1.27)          | 1.02 (0.99-1.06)    |
| Sinilnikova et al., 2009| 3,959/3,052     | 0.97 (0.80-1.16)          | 1.01 (0.92-1.11)          | 1.00 (0.93-1.08)    |
| Cavallone et al., 2008| 157/112            | 1.29 (0.52-3.21)          | 1.00 (0.62-1.63)          | 1.04 (0.71-1.53)    |
| Buyru et al., 2010 | 240/192             | 1.48 (0.73-3.00)          | 1.45 (0.98-2.15)          | 1.34 (0.99-1.81)    |
| **Sinilnikova et al., 2009**| 3,959/3,052   | 0.97 (0.80-1.16)          | 1.01 (0.92-1.11)          | 1.00 (0.93-1.08)    |
| Cavallone et al., 2008| 157/112            | 1.29 (0.52-3.21)          | 1.00 (0.62-1.63)          | 1.04 (0.71-1.53)    |
| Baynes et al., 2007 | 2,023/2,197        | 1.04 (0.82-1.30)          | 1.05 (0.93-1.18)          | 1.04 (0.95-1.14)    |
| Tommiska et al., 2005| 1,351/733         | 1.02 (0.72-1.43)          | 0.93 (0.78-1.11)          | 0.96 (0.83-1.10)    |
| Akkiprik et al., 2009| 95/108             | 0.39 (0.14-1.12)          | 1.38 (0.78-2.42)          | 1.02 (0.65-1.91)    |
| **Costa et al., 2008**| 248/646           | 0.81 (0.49-1.32)          | 0.86 (0.64-1.16)          | 0.87 (0.69-1.10)    |
| Buyru et al., 2007  | 115/63              | 1.44 (0.58-3.57)          | 1.77 (0.96-3.29)          | 1.52 (0.96-2.43)    |
| Johnson et al., 2007 | 472/2,462       | 1.17 (0.79-1.74)          | 0.98 (0.80-1.19)          | 1.01 (0.87-1.19)    |
| Schmidt et al., 2007| 5,191/3,834       | 1.01 (0.86-1.18)          | 1.05 (0.96-1.14)          | 1.03 (0.96-1.10)    |
| Kalemi et al., 2005 | 42/51              | 2.52 (0.69-9.26)          | 6.35 (2.54-15.84)         | 3.29 (1.73-6.25)    |
| Ohayon et al., 2005 | 475/302            | 1.64 (0.97-2.76)          | 1.25 (0.94-1.67)          | 1.27 (1.01-1.60)    |
| **Europe**        | Σ=16,387/15,608     | 1.03 (0.95-11.25)         | 1.13 (1.00-1.27)          | 1.02 (0.99-1.06)    |
| Buyru et al., 2003  | 115/76              | 1.61 (0.69-3.73)          | 3.23 (1.7-6.00)           | 2.09 (1.36-3.22)    |
allele as dominant (Figure 3 and Table 1). In agreement with our results, the PP genotype was previously associated with higher risk for breast cancer (Huang et al. 2003; Rajkumar et al. 2008). Among unselected breast cancer patients, the PP genotype also predicted poor survival and a 2-fold increased risk of death (Tommiska et al. 2005).

The P allele has been associated with earlier breast cancer onset in BRCA1/2 mutation carriers (Tommiska et al. 2005; Martin et al. 2003), probably due to the lower ability of the P variant to induce apoptosis in genotoxic stress (Chang-Claude et al. 2009; Dumont et al. 2003). However, most of the studies selected for this meta-analysis have failed to detect any implication of R72P to breast cancer risk. Among most of the selected references, no risk modification by R72P was found in wild type BRCA1/2 and mutation carriers, even if the age of diagnosis or tumor stage were regarded (Sinilnikova et al. 2009; Lum et al. 2008; Cavallone et al. 2008; Baynes et al. 2007; Tommiska et al. 2005). Our overall data showed an association of risk increase with PP genotype, but not with the alleles alone (R vs. P; OR = 1.02; 95% CI 1.00-1.05), as described in Table 1. The lack of implication concerning P allele alone might be explained by the R allele in the heterozygous, because the R variant may act in a codominant mode to decrease breast cancer risk and to detain the onset in sporadic cases (Lum et al. 2008). Although our overall data show no association with the alleles alone, the analysis of 2,570 cases and 2,833 controls from Asia demonstrated a markedly increase of the R allele frequency in breast cancer

Table 1 Meta-analysis of the R72P polymorphism of the gene TP53 on breast cancer (Continued)

| Reference | Cases/Controls | RR (95% CI) | OR (95% CI) | OR (95% CI) |
|-----------|---------------|-------------|-------------|-------------|
| Suspitsin et al., 2003 | 529/393 | 0.86 (0.52-1.41) | 1.04 (0.80-1.35) | 1.00 (0.81-1.23) |
| Wang-Gohrke et al., 2002 | 552/543 | 0.82 (0.53-1.26) | 0.85 (0.67-1.07) | 0.87 (0.72-1.05) |
| **Overall** | 25,629/26,633 | 1.09 (0.98-1.22) | *1.11 (1.02-1.21) | 1.02 (1.00-1.05) |
| **Heterogeneity** | | | | |
| $\chi^2$ = 80.19 | | $\chi^2$ = 146.02 | $\chi^2$ = 6.54 | |
| $P$ = 0.0002 | | | | $P$ = 0.088 |

Figure 3 Meta-analysis evaluation of the dominant model RR vs. RP + PP.
patients (R vs. P; OR = 1.09; 95% CI 1.01-1.17), as detailed in Table 1.

Ethnic and geographical nonspecific factors, further to allele frequencies variations in different health populations, have been argued as the reason to the controversial data on R72P role in breast cancer (Dokianakis et al. 2000; Lum et al. 2008; Huang et al. 2003). Worth of note in this regard is that, in our meta-analysis, R allele was the most frequent in patients and control subjects, featuring the allele frequencies as a potential ethnic or geographical risk factor. By pooling all studies per continent, we performed the analyses of the dominant models and the genotypes using the fixed-effect model. Our overall results showed no association of the R72P polymorphism with breast cancer, but Asian patients had an increased risk associated with the dominant model RR + RP (OR = 1.23; 95% CI 1.07-1.41), as described in Table 2. These remarkable data concerning RR + RP genotypes and R allele in Asia are in agreement with the reports that R variant increased breast risk in patients from China (Weston & Godbold 1997; Li et al. 2002) and India (Gochhait et al. 2007). In contrast, previous meta-analysis designed studies failed to correlate the R72P polymorphism with breast cancer (Ma et al. 2006; Zhuo et al. 2009), even when subjects were stratified by ethnicity or source of controls (Ma et al. 2011).

In conclusion, we found significant association between the R72P polymorphism in the TP53 gene and the breast cancer risk. The overall data showed an increased risk due to the R allele dominant model, but not in Asia where the risk was associated with the R allele and R dominant model. The present meta-analysis is supported by a large sample size composed by 25,629 cases and 26,633 controls from 41 studies.

Competing interests
The authors declare that they have no competing interests. There are no financial or personal interests that might be viewed as inappropriate influences on the work presented herein. This manuscript was completely financed by governmental and nonprofit institutions, Foundation for the Support of Research in the State of Goiás (FAPEG), Coordination for the Advancement of Higher Education Staff (CAPES) and Brazilian Ministry of Education (MEC).

Table 2 Meta-analysis of the R72P polymorphism of the gene TP53 on breast cancer, by pooling data per continent

|       | RR vs. RP | RR vs. PP | RP vs. PP | RR+RP vs. PP | RR vs. RP+PP |
|-------|-----------|-----------|-----------|--------------|--------------|
| Africa| 1.41 (0.90-2.22) | 1.30 (0.69-2.44) | 0.99 (0.54-1.83) | 1.05 (0.65-1.86) | 1.32 (0.86-2.01) |
| America| 1.04 (0.87-1.23) | 1.04 (0.82-1.33) | 1.01 (0.88-1.16) | 0.98 (0.86-1.11) | 0.96 (0.90-1.03) |
| Asia| 1.05 (0.88-1.26) | 1.24 (0.87-1.78) | 1.15 (0.85-1.57) | *1.23 (1.07-1.41) | 1.04 (0.93-1.17) |
| Europe| 1.09 (0.97-1.22) | 1.10 (0.93-1.31) | 1.01 (0.92-1.11) | 1.04 (0.95-1.13) | 1.03 (0.98-1.08) |
| Overall| 1.01 (0.97-1.04) | 1.05 (0.99-1.12) | 1.05 (0.99-1.12) | 1.06 (0.99-1.12) | 1.05 (0.98-1.05) |

Heterogeneity

|       | χ² = 3.91 | χ² = 5.42 | χ² = 5.78 | χ² = 6.15 | χ² = 4.53 |
|-------|-----------|-----------|-----------|-----------|-----------|
| P     | 0.27      | 0.14      | 0.12      | 0.10      | 0.21      |

Authors’ contributions
The work presented here was carried out in collaboration between all authors. AMTCS, MLG and SMB conceived and designed the study. MLG, SMB, JABC and AMTCS performed the effect size calculations and moderation tests. AMTCS wrote the paper. FMA and CASTVC reviewed the manuscript. All authors have contributed to, seen and approved the manuscript.

Acknowledgements
The authors gratefully acknowledge the financial support of Brazilian Ministry of Education (MEC) through University for Everyone Program (PROUNI) fellowship to Meire Luzia Gonçalves and Foundation for the Support of Research in the State of Goiás (FAPEG) and Coordination for the Advancement of Higher Education Staff (CAPES) through fellowship to Jacqueline Andrela Bernadés Leão Cordeiro and Cesar Augusto Sam Tiago Vilanova-Costa.

Author details
1Departamento de Medicina, Pontifícia Universidade Católica de Goiás, Av. Universitária 1.069, Setor Universitário, Goiânia, Goiás CEP 74.605-010, Brazil. 2Faculdade de Enfermagem, Universidade Federal de Goiás, Goiânia, Goiás CEP 74605-060, Brazil. 3Laboratório de Oncogenética e Radiobiologia, Hospital Araújo Jorge, Associação de Combate ao Câncer em Goiás, Goiânia, Goiás CEP 74605-070, Brazil. 4Unidade Universitária de Ciências Exatas e Tecnológicas, Universidade Estadual de Goiás, Anápolis, Goiás CEP 75132-400, Brazil. 5Programa de Pós-Graduação Stricto Sensu em Ciências Ambientais e Saúde, Pontifícia Universidade Católica do Goiás, Goiânia, Goiás CEP 74605-140, Brazil.

Received: 10 November 2014 Accepted: 11 November 2014 Published: 17 December 2014

References
Akkigikil M, Sonmez O, Gulluoglu BM, Caglar HB, Kaya H, Demirkalem P, Abacioglu U, Sengoz M, Siv A, Özer A (2009) Analysis of p53 gene polymorphisms and protein over-expression in patients with breast cancer. Pathol Oncol Res 15:359–368
Alawadi S, Ghabreau L, Alsaleh M, Abdulaziz Z, Rafeek M, Alkhalaf M (2011) P53 gene polymorphisms and breast cancer risk in Arab women. Med Oncol 28(3):709–715
Aoki MN, da Silva AHAC, Amarante MK, Do Val Carneiro JL, Fungaro MH, Watanabe MA (2009) CCR5 and p53 codon 72 gene polymorphisms: implications in breast cancer development. Int J Mol Med 23:429–435
Baynes C, Healey CS, Pooley KA, Scollen S, Luben RN, Thomson DJ, Pharoah PD, Easton DF, Ponder BA, Dunning AM (2007) SEARCH breast cancer study: common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk. Breast Cancer Res 9(2):R27
Bergamaschi D, Samuels Y, Sullivan A, Breyssens H, Bisso A, Del Sal G, Syed N, Smith P, Gasco M, Crook T, Lu X (2006) iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet 38(10):1133–1141
Bisof V, Salihovic MP, Narancic NS, Skacir-Juric T, Jakic-Razumovic J, Janicicovic B, Turek S, Rudan P (2010) TP53 gene polymorphisms and breast cancer in Croatian women: a pilot study. Eur J Gynaecol Oncol 31:539–544

Böhnning D, Malbaini U, Dietz E, Schlattmann P, Wiatrowkgsaem C, Biggeri A (2002) Some general points in estimating heterogeneity variance with the DeSio/monai-Laird estimator. Biostatistics 3(4):445–457

Buyu N, Tugi H, Dalay N (2003) P53 codon 72 polymorphism in breast cancer. Oncol Rep 10:711–714

Buyu N, Attinisk J, Demokan S, Dalay N (2007) p53 genotypes and haplotypes associated with risk of breast cancer. Cancer Detect Prev 31:207–213

Cavallone L, Arcand SL, Maudarg C, Ghadrian P, Mones-Masson AM, Provencher D, Tonin PN (2008) Haplotype analysis of TP53 polymorphisms, Arg2Pro and Ins/6Ins, in BRCA1 and BRCA2 mutation carriers of French Canadian descent. BMC Cancer 8:96

Chang-Claude J, Ambrusso CB, Lilla C, Kroop S, Helmbold I, von Fournier D, Haase W, Sautter-Bihl ML, Wenz F, Schmeizer P, Popanda O (2009) Genetic polymorphisms in DNA repair and damage response genes and late normal tissue complications of radiotherapy for breast cancer. Br J Cancer 100:1603–1668

Conn VS, Ruppan TM, Phillipps LJ, Chase J-A (2012) Using meta-analyses for comparative effectiveness research. Nurs Outlook 60:182–190

Costa S, Pinto D, Pereira D, Rodrigues H, Cameselle-Teijeiro J, Medeiros R, Schmitt F (2008) Importance of TP53 codon 72 polymorphism 203 codon 72 polymorphism and risk of breast cancer. Carcinogenesis 29(3):357–365

Cox DG, Deer D, Guo Q, Tworoger SS, Hankinson SE, Hunter DJ, De Vivo I (2007) p53 genotypes and haplotypes in two independent populations. Br J Cancer 92:1989–1994

Damin AP, Frazzon AP, Damin DC, Roehe A, Hermes V, Zettler C, Alexandre CO (2003) P53 codon 72 polymorphism in breast cancer. Cancer Detect Prev 30:523–530

Dapian LA, Arcand SL, Maudarg C, Ghadirian P, Mes-Masson AM, Provencher D, Buyru N, Altinisik J, Demokan S, Dalay N (2007) p53 genotypes and haplotypes in breast cancer risk. Cancer Genet Cytofent 173:18–22

Goldin H, Chih H, Lee S, Wang Y, Lin C, Qu Y, Lin X, Zhai S, Wang X, Qin J, Chen W, Jin G, Liu J, Gao J, Wang X, Wei K, Qiu H, Chen S (2006) Joint effects of single nucleotide polymorphisms in P53BP1 and p53 on breast cancer risk in a Chinese population. Carcinogenesis 27:766–771

Huang XE, Hamajima N, Katsuda N, Matsuo K, Hirose K, Mizutani M, Iwata H, Chen Y-F, G, Hei Y, Deng H-W (2012) The impact of imputation on meta-analysis of genome-wide association studies. PLoS One 7(4):e34486

Huang XE, Hamajima N, Katsuda N, Matsuo K, Hirose K, Mizutani M, Iwata H, Chen Y-F, G, Hei Y, Deng H-W (2012) The impact of imputation on meta-analysis of genome-wide association studies. PLoS One 7(4):e34486

Kalemi-TG, Lambropoulos AF, Gueorguiev M, Christia S, Papazis KT, Kotsis A (2005) The association of p53 polymorphisms and p53 codon 72, Her 2 655 codon polymorphisms with breast cancer in Northern Greece. Cancer Lett 222:57–65

Kara N, Karakus N, Ulusoy AO, Ozsanl C, Gungor B, Bogo H (2010) P53 codon 72 and HER2 codon 655 polymorphisms in Turkish breast cancer patients. DNA Cell Biol 29(7):387–399

Katar A, Thelma BK, Murthy NS, Heda I, Jain N, Gopalakrishna V, Husain SA, Das BC (2003) Polymorphism of the p53 codon 72 Arg/Pro and the risk of HPV type 16/18-associated cervical and oral cancer in India. Mol Cell Biochem 252:117–124

Kazemi M, Salehi Z, Chakosri RJ (2009) TP53 Codon 72 polymorphism and breast cancer in northern Iran. Oncol Res 18(1):25–30

Khadang B, Fattahi MJ, Tali E, Dehaghami AS, Ghaderi A (2007) Polymorphism of TP53 codon 72 showed no association with breast cancer in Iranian women. Cancer Genet Cytofent 173:38–42

Li T, Ju ZM, Guo M, Wu QJ, Chen KN, Xing HP, Mei Q, Ye Q (2002) p53 codon 72 polymorphism (C/G) and the risk of human papillomavirus-associated carcinomas in China. Cancer 95(12):2571–2576

Li Y, YG Pei, Deng HW (2012) The impact of meta-analysis on p53 polymorphism and breast cancer risk. Oncol Rep 27(4):1433–1439

Limon JM, Serafin PV, Silva IC, Domingue NM (2006) Estudo do polimorfismo genético no gene p53 (codon 72) em câncer colorretal. A Gastroenterol 431(8–12)

Lum SS, Chua HN, Li H, Li WF, Rao N, Wei J, Shao Z, Sabathy K (2008) MDM2 SNP309 G allele increases risk but the T allele is associated with earlier onset age of sporadic breast cancers in the Chinese population. Carcinogenesis 29:574–581

Ma H, Hu Z, Zhai X, Wang S, Wang X, Qin J, Chen W, Jin G, Liu J, Gao J, Wang X, Wei K, Qiu H, Shen H (2006) Joint effects of single nucleotide polymorphisms in P53BP1 and p53 on breast cancer risk in a Chinese population. Carcinogenesis 27:766–771

Ma Y, Yang J, Liu Z, Zhang P, Yang J, Wang Y, Qin H (2011) No significant association between the TP53 codon 72 polymorphism and breast cancer risk: a meta-analysis of 21 studies involving 24,063 subjects. Breast Cancer Res Treat 125:201–205

Mabrouk I, Baccouche S, Al-Abed R, Mokdad-Garroui R, Mosbah A, Said S, Daoud J, Frikha M, Jildi R, Garroui A (2003) No evidence of correlation between p53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients. Ann NY Acad Sci 1010:744–770

Manning AK, Valley ML, Liu C-T, Rice K, An P, Liu Y, Miljkovic J, Rasmussen-Tonell K, Harris TR, Province MA, Bereoci IB, Florez JC, Meigs JB, Cupples LA, Dupuis J (2011) Meta-analysis of Environment-Interaction joint estimation of SNP and SNP × Environment regression coefficients. Genet Epidemiol 35:11–18

Martin A-M, Kanestey PA, Amirmirana B, Collignon TA, Athanasidias G, Shih HA, Gerreo MR, Calzone K, Rebbeck TR, Weber BL (2003) Germline TP53 mutations in breast cancer families with multiple primary cancers is TP53 a modifier of BRCA1? Med Genet 40:e164

Menzel HU, Sarmanova J, Soucek P, Berberich R, Grunewald K, Hahn M, Kraft H (2008) Importance of ACCOQ1 polymorphism with spontaneous breast cancer in two independent populations. Br J Cancer 90:1989–1994

Noma C, Miyoshi Y, Taguchi T, Taniyama Y, Noguchi S (2004) Association of p53 genetic polymorphism (Arg2Pro) with estrogen receptor positive breast cancer risk in Japanese women. Cancer Lett 210:197–203

Ohayon T, Gesaroni-Baruch R, Papa MZ, Distelman Menachem T, Eisenberg Barzilai S, Friedman E (2006) The R72P p53 mutation is associated with familial breast cancer in Jewish women. Br J Cancer 92:1144–1148

Oliver M, Eeles R, Holstein M, Khan MA, Harris CC, Hainaut P (2002) The IARC tp53 database: New online mutation analysis and recommendations to users. Hum Mutat 18(6):607–614

Olawugbemiga LA, Oluwole A, Kayode AAR (2012) Seventeen years after BRCA1: what is the BRCA mutation status of the breast cancer patients in Africa? – a systematic review. Springer Plus 1:83

Osorio A, Pollán M, Pita G, Schmutzler RK, Versmold H, Rothenbacher D, Engel C, Meindl A, Arnold N, Presleier-Adams S, Niederacher D, Hofmann W, Gaidzik D, Jakubowska A, Haman N, Lubinski J, Toloczko-Grabarek A, Cebulski C, Debniak T, Llort G, Yannoukakos D, Díez O, Peissel B, Peterlongo P, Radice P, Heikkinen T, Nevanlinna H, Mai PL, Louden M, McCaffey L, Antoniou AC et al. (2008) Evaluation of the polymorphisms Ins16bp and Arg2Pro in p53 as breast cancer risk modifiers in BRCA1 and BRCA2 mutation carriers. Br J Cancer 99:974–977

Petitecan A, Mi A, Bi D-O, Hainaut P, Oliver M (2007) TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26(15):2157–2165

Gonçalves et al. P2013, 3:749
http://www.springerplus.com/content/3/1/749
Page 7 of 8
Pinto Y, Ibáñez M, Rangel N, Ramírez S, Sánchez W, Vanegas D (2007) Polimorfismos del gen P53 en cáncer mamario familiar en una población colombiana. Rev Colomb Cir 22:17–26

Rajkumar T, Samson M, Rama R, Sridevi V, Mahji U, Swaminathan R, Nancy NK (2008) TGFbeta1 (Leu10Pro), p53 (Arg72Pro) can predict for increased risk for breast cancer in south Indian women, and TGFbeta1 Pro (Leu10Pro) allele predicts response to neo-adjuvant chemo-radiotherapy. Breast Cancer Res Treat 112:81–87

Schmidt MK, Reinicke S, Broeks A, Braaf LM, Hogervorst FB, Tollenaar RA, Johnson N, Fletcher O, Petto J, Tommiska J, Blomqvist C, Nevanlinna HA, Healey CS, Dunning AM, Pharoah PD, Easton DF, Dörk T, Van’t Veer LJ (2007) Breast cancer association consortium: Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium. Cancer Res 67:9584–9590

Schmidt MK, Tommiska J, Broeks A, Leeuwen FEV, Veer LM, Pharoah PD, Easton DF, Shah M, Humphreys M, Dörk T, Reinicke SA, Fagerholm R, Blomqvist C, Nevanlinna H (2009) Combined effects of single nucleotide polymorphisms TP53 TP53 Arg72Pro and MDM2 SNP309, and p53 expression on survival of breast cancer patients. Breast Cancer Res 11(6):R89

Siddique MM, Balram C, Fiszer-Maliszewska L, Aggarwal A, Tan A, Tan P, Soo KC, Sabapathy K (2005) Evidence for selective expression of the p53 codon 72 polymorphs: implications in cancer development. Cancer Epidemiol Biomarkers Prev 14:2245–2252

Singh V, Rastogi N, Mathur N, Singh K, Singh MP (2008) Association of polymorphism in MDM-2 and p53 genes with breast cancer risk in Indian women. Ann Epidemiol 18:48–57

Sinilnikova OM, Antoniou AC, Simard J, Healey S, Léoné M, Sinnett D, Spurdle AB, KConFab, Greene MH, Loud JT, Lejbkowicz F, Andrulis IL, OCGN, Domchek SM, Nathanson KL, Radice P, Konstantopoulou I, Blanco I, Laborde AL, Durán M, Osorio A, Benitez J, Hogervorst FB, van Os TA, Gille HU, Healey CS, Dunning AM, Pharoah PD, Easton DF, Dörk T, Van’t Veer LJ, HEBON et al (2009) The TP53 Arg72Pro and MDM2 309G4T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Br J Cancer 101:1456–1460

Sprague BL, Trentham-Dietz A, Garcia-Closas M, Newcomb PA, Titus-Ernstoff L, Hampton JM, Chanock SJ, Haines JL, Egan KM (2007) Genetic variation in TP53 and risk of breast cancer in a population-based case control study. Carcinogenesis 28:1680–1686

Suresh K, Venkatesan R, Chandirasekar R, Kumar BL, Sasikala K (2011) Association of Trp53 arg72pro polymorphic variants with breast cancer – a case control study in south Indian population. Biol Med 3(1):15–22

Suspitsin EN, Buslov KG, Grigoriev MY, Ishutkina JG, Ulibina JM, Gorodinskaya VM, Pozharisski WM, Bortolussi LA, Chan QC, Vigh N, Peto J, Langman MJ, Healy CS, Dunning AM, Pharoah PD, Easton DF, Dörk T, Van’t Veer LJ, HEBON et al (2009) The TP53 Arg72Pro polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 19(8):2070–2075

Trifa F, Karray-Chouayekh S, Mabrouk I, Baccouche S, Khabir A, Sellami-Boudawara T, Gargouri A, Mokdad-Gargouri R (2010) Haplotype analysis of the p53 polymorphisms: Arg72Pro, Ins16bp and G13964C in Tunisian patients with familial or sporadic breast cancer. Cancer Epidemiol 34(2):184–188

Weston A, Godbold JH (1997) Polymorphisms of H-ras-1 and p53 in breast cancer and lung cancer: a meta-analysis. Environ Health Perspect 105:919–926

Zhuo W, Zhang Y, Xiang Z, Cai L, Chen Z (2009) Polymorphisms of TP53 codon 72 with breast carcinoma risk: evidence from 12226 cases and 10782 controls. J Exp Clin Cancer Res 28:115

doi:10.1186/2193-1801-3-749

Submit your manuscript to a SpringerOpen journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Immediate publication on acceptance
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Visit springeropen.com to submit your manuscript.